New California Law Increases Access to Biomarker Testing for Late-Stage Cancer Patients

The selection of targeted therapies for cancer treatment depends on access to comprehensive biomarker testing; for some patients, this testing can literally mean the difference between life and death. Biofidelity’s Chief Medical Officer Wendy Levin talks with OncologyTube about why a new California law that aims to increase timely access to genomic testing for late-stage cancer patients is a “step in the right direction,” and how Biofidelity’s technology will help oncologists offer the benefits of precision medicine to more patients.

Watch on Oncology Tube